Alphamab Oncology
HKEX:9966
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Alphamab Oncology
Total Liabilities & Equity
Alphamab Oncology
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Alphamab Oncology
HKEX:9966
|
Total Liabilities & Equity
¥2.4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Total Liabilities & Equity
¥57.3B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Total Liabilities & Equity
¥37.3B
|
CAGR 3-Years
29%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Total Liabilities & Equity
¥7.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Total Liabilities & Equity
¥16B
|
CAGR 3-Years
43%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Total Liabilities & Equity
¥3.5B
|
CAGR 3-Years
52%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Alphamab Oncology
Glance View
Alphamab Oncology is an investment holding company. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2019-12-12. The firm is a full-industry chain enterprise specializing in research, development, manufacture, and commercialization of innovative tumor immunobiology macromolecular targeted drugs. The firm has bio-innovation drug development technology platform, including protein engineering platform, multi-functional antibody development platform and antibody screening platform. The firm operates its businesses in both domestic and overseas markets.
See Also
What is Alphamab Oncology's Total Liabilities & Equity?
Total Liabilities & Equity
2.4B
CNY
Based on the financial report for Dec 31, 2025, Alphamab Oncology's Total Liabilities & Equity amounts to 2.4B CNY.
What is Alphamab Oncology's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
-2%
Over the last year, the Total Liabilities & Equity growth was 5%. The average annual Total Liabilities & Equity growth rates for Alphamab Oncology have been 4% over the past three years , -2% over the past five years .
